English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine Clinical Trials
HighTide Therapeutics to Present Analyses of Phase 2 MASH Study at AASLD's The Liver Meeting 2024
Oct 25, 2024 08:57 HKT
康哲藥業入選2024年度「中國醫藥上市公司ESG競爭力」系列榜單
Oct 21, 2024 19:18 HKT
康哲藥業:蘆可替尼乳膏(白癜風)大灣區首批處方落地
Oct 18, 2024 14:54 HKT
CanSino Receives Another Strong Boost
Oct 09, 2024 19:29 HKT
GEN Announces Positive Phase 2 Clinical Trial Results for GN-037 Topical Cream in Patients With Mild to Moderate Plaque Psoriasis
Sep 25, 2024 21:00 HKT
康哲藥業:磷酸蘆可替尼乳膏(白癜風)中國上市許可申請已獲受理
Sep 24, 2024 21:46 HKT
君聖泰醫藥亮相香港國際生物科技論壇
Sep 17, 2024 15:00 HKT
君聖泰醫藥亮相香港國際生物科技論壇
Sep 16, 2024 14:53 HKT
君圣泰医药亮相香港国际生物科技论坛
Sep 13, 2024 18:22 HKT
EASD 2024 | 君圣泰医药口头报告熊去氧胆小檗碱(HTD1801)在T2DM中的两项事后分析
Sep 11, 2024 11:51 HKT
EASD 2024 | HighTide Therapeutics Presents Oral Reports of Phase 2 Studies, Highlighting Benefits of Berberine Ursodeoxycholate (HTD1801)
Sep 11, 2024 11:34 HKT
EASD 2024 | 君聖泰醫藥口頭報告熊去氧膽小檗碱(HTD1801)在T2DM中的兩項事後分析
Sep 11, 2024 11:16 HKT
2024 CSE - 君聖泰醫藥分享天然產物在代謝性疾病的創新成果
Aug 12, 2024 17:55 HKT
2024 CSE | 君圣泰医药分享天然产物在代谢性疾病的创新成果
Aug 12, 2024 17:32 HKT
Avance Clinical 任命亚洲区域总监,作为全球扩展计划的一部分
Jul 24, 2024 08:00 HKT
Avance Clinical 任命亞洲區域總監,作為全球擴展計畫的一部分
Jul 24, 2024 08:00 HKT
Avance Clinical, 글로벌 확장 프로그램의 일환으로 아시아 지역 이사 임명
Jul 24, 2024 08:00 HKT
Sirnaomics Announces Completion of IND-Enabling Studies of Safety and Efficacy for STP125G with NHP Models, Targeting ApoC3 for Treatment of Cardiovascular Diseases
Jul 23, 2024 19:16 HKT
Sirnaomics宣布完成针对靶向APOC3用于治疗心血管疾病的STP125G 在非人灵长类动物模型中安全性和有效性的IND准备阶段研究
Jul 23, 2024 18:26 HKT
Sirnaomics宣佈完成針對靶向APOC3用於治療心血管疾病的STP125G 在非人靈長類動物模型中安全性和有效性的IND準備階段研究
Jul 23, 2024 17:52 HKT
Next >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: